Ovarian Cancer (OC) is the fifth most common malignancy diagnosed in women, and the most common gynecological cancer, with an estimated 225,000 new cases diagnosed globally in 2008. Rates are particularly high in developed countries, and especially in Northern Europe. However, substantial improvements in the treatment of OC have been made in recent decades, through the introduction of platinum-based compounds, and improvements in surgery.
This has resulted in an increase in the percentage of patients that survive for five years, from approximately 20% in the 1970s, to the current rate of 45%. However, there have been no significant improvements in the treatment of the disease in recent years, with platinum-based compounds remaining the standard of care for firstand usually second-line treatment.
The differences between many of these products are relatively nuanced, and must be understood fully by companies seeking to position a novel drug in this market. This tabular heatmap framework, designed to provide an easily digestible summary of these clinical characteristics, provides detailed information on all late-stage clinical trial results for products in the OC market and late-stage pipeline. These are split along therapy lines, and are therefore reflective of the treatment algorithm.
All safety and efficacy endpoints reported in these trials are displayed, for both the drug and comparison groups. In addition, key study characteristics such as the size, composition and patient segment of the study population are provided. These results are presented in a visually accessible, color-coded manner in order to maximize ease of use.
The accompanying text provides a detailed analysis of the clinical benchmarks set by the current market landscape, and the anticipated changes to these benchmarks, and to the treatment algorithm, as a result of the late-stage pipeline.
Reasons to buy
Table of Contents
1 Table of Contents
1 Table of Contents 2
2 Introduction 3
2.1 Report Guidance 4
3 Marketed Products 5
3.1 First-Line Therapy 5
3.2 Maintenance Therapy 6
3.3 Recurrent Disease 6
4 Pipeline Products 9
4.1 Changes to First-Line Therapy, 2015-2022 9
4.2 Changes to Maintenance Therapy, 2015-2022 9
4.3 Changes to Recurrent Disease, 2015-2022 9
5 Appendix 11
5.1 Abbreviations 11
5.2 References 12
5.3 Research Methodology 15
5.4 Contact Us 16
5.5 Disclaimer 16
Make an enquiry before buying this Report
Please fill the enquiry form below.